Menu Search
Equities

Alnylam Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DUL:BRN

Alnylam Pharmaceuticals Inc

Actions
  • Price (CHF)294.88
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change--
  • Beta0.3601
Data delayed at least 15 minutes, as of Jan 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

  • Revenue in USD (TTM)3.21bn
  • Net income in USD43.57m
  • Incorporated2003
  • Employees2.23k
  • Location
    Alnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
  • Phone+1 (617) 551-8200
  • Fax+1 (617) 551-8101
  • Websitehttps://www.alnylam.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.